Cancer biomarker Market Research Report- Global Forecast till 2023

Cancer biomarker Market Research Report- Global Forecast till 2023

ID: MRFR/HC/3935-CRR | January, 2018 | Region: Global | 85 pages | Cooked Research Reports

Global Cancer Biomarker Market Research Report: By Types (Protein Biomarker, Genetic Biomarker), By Applications (Diagnostic, Prognostic, Therapeutic), By End Users (Pharmaceutical and Biotechnology Companies, Diagnostic Companies) – Forecast till 2023


Market Scenario


Cancer is a diverse disease that can originate in different organs and tissues, with each type being associated with different risk factors. Cancer biomarkers are molecules released during the presence of a tumor or a particular indication of cancer in the body. These can either be substance, molecule or a physical event that indicates the existence of cancerous cells in the body. These molecules are generally found in tissues, urine, serum, blood, and other body fluids that indicate any abnormal process or a disease.

The cancer biomarker market is primarily driven by factors including adoption of western lifestyles in the developing regions, extensive research of cancer biomarkers, encouragement for biomarker development by FDA, improved precision and speed of diagnosis, high investment through government and private funds in cancer-related research, and development of highly specific drugs. The global population has witnessed an alarming surge in cancer, with about 14 million new cancer cases reported each year. According to WHO, it is anticipated to further increase over the next two decades by 70% with 22 million new cancer cases in 2012.

Cancer treatment is primarily responsible of health care costs in the world and thus is one of the key restraining factor in the global cancer biomarkers market. Many patients who are suffering from cancer cannot afford its treatment. Therefore, reimbursement issues and the need for immediate processing are restraining this market. Moreover, the success rate of clinical trials are low of biomarkers is the major factor hindering the cancer biomarker market.  There are high investments and low benefit-cost ratio associated with the development of cancer biomarkers which is making it one of the major restraints of cancer biomarkers market.

The global cancer biomarker market is expected to grow at a CAGR of 15.8% during the forecast period, 2017-2023.

Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories 


Figure 1- Market Synopsis of the Global Cancer biomarker Market Research, by Region, 2016 (%)

Cancer biomarker Market


Sources- WHO, Cancer Research UK, American Cancer Society, press release, annual report


 


Segmentation


The global cancer biomarker market is segmented on the basis of types, applications and end users.


On the basis of types, the market is segmented into protein biomarker, genetic biomarker and others


On the basis of application, the market is segmented into diagnostic, prognostic and therapeutic. The diagnostic sub-segment is further classified into imaging and non- Imaging.


On the basis of end users, the market is segmented into pharmaceutical and biotechnology companies, diagnostic tool companies, healthcare it/big data companies, clinical laboratories           


Regional Analysis


The global cancer biomarker market is segmented on the basis of regions: America, Europe, Asia Pacific, and the Middle East & Africa.

The cancer biomarker market in North America is expected to hold the largest share by 2025 due to the high prevalence of cancer and huge investments considering the detection and diagnosis of cancer. The United States is the dominating market due to the growing demand for investment in research and development, enhancing prevalence rate of cancer and key region considering medical tourism. A large share of this geographic segment is mainly attributed to the increasing government support for the discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Europe holds the largest cancer biomarker market whose market is driven by the increasing number of clinical trials, and availability of funds for research. There is an increasing demand for new diagnostic tools and devices across the European countries such Germany, France, and the U.K.

On the other hand, the Asia Pacific market is anticipated to be the fastest growing region owing to the availability of skilled professional such as technicians and diagnostic specialist. The growing population in countries such as China and India, rising investments by public and private sectors in the cancer diagnosis and treatment, as well as the increasing prevalence of cancer in the Asia Pacific region are acting as the major drivers for the development and expansion of the cancer biomarkers market in Asia Pacific. Rise in medical tourism considering the cancer diagnosis and treatment is also impacting the growth of cancer biomarkers market in Asia Pacific region.

On the other hand, the Middle East & Africa hold the least share of the market due to the low prevalence of cancers in the region and limited availability of funds and availability of medical facilities. The Middle East has a huge share for the cancer biomarker market due to the presence of well-developed countries like Kuwait, Qatar, Oman, and Saudi Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth in near future.

Market Assessment



Global Cancer biomarker Market


Sources- WHO, cancer research U.K, American Cancer Society, press release, annual report


 


Key Players in Global Cancer Biomarker Market


Some of key the players in the market are  F. Hoffmann-La Roche AG (Switzerland), Becton Dickinson (U.S.), Abbott Laboratories (U.S.), PerkinElmer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.S.), QIAGEN N.V (U.S.), Novartis AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Illumina Inc. (U.S.)



License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6.1 Introduction

6.2 Protein Biomarker

6.3 Genetic Biomarker

6.4 Others

7.1 Introduction

7.2 Diagnostic

7.2.1 Imaging

7.2.2 Non- Imaging

7.3 Prognostic

7.4 Therapeutic

8.1 Introduction

8.2 Pharma & Biotech Companies

8.3 Diagnostic Tool Companies

8.4 Healthcare IT/Big Data Companies

8.5 Clinical Laboratories

9.1 Introduction

9.2 America

9.2.1 North America

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11.1 F. Hoffmann-La Roche AG

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Becton Dickinson

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 PerkinElmer, Inc.

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Bristol-Myers Squibb

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Bio-Rad Laboratories

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Eli Lilly and Company

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Merck & Co., Inc

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Pfizer Inc.

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.10 GlaxoSmithKline plc.

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 QIAGEN N.V

11.11.1 Company Overview

11.11.2 Financials

11.11.3 Products

11.11.4 Strategy

11.11.5 Key Developments

 11.12 Novartis AG

11.12.1 Company Overview

11.12.2 Financials

11.12.3 Products

11.12.4 Strategy

11.12.5 Key Developments

11.13 Thermo Fisher Scientific Inc.

11.13.1 Company Overview

11.13.2 Financials

11.13.3 Products

11.13.4 Strategy

11.13.5 Key Developments

11.14 Illumina Inc.

11.14.1 Company Overview

11.14.2 Financials

11.14.3 Products

11.14.4 Strategy

11.14.5 Key Developments

11.15 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Medical End Users Industry

Chapter 13 Appendix

Table 1 Cancer Biomarker Industry Synopsis, 2017 – 2023

Table 2 Global Cancer Biomarker Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Cancer Biomarker Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 5 Global Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 6 Global Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 8 North America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 9 North America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 11 US Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 12 US Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Market by Type, 2017 – 2023, (USD Million)

Table 14 Canada Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 15 Canada Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 17 South America Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 18 South America Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 20 Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 21 Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 23 Western Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 24 Western Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Cancer Biomarker Market by Type, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Cancer Biomarker Market by Application, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Cancer Biomarker Market by End Users, 2017 – 2023, (USD Million)

Figure 1 Research Process

Figure 2 Segmentation for Global Cancer Biomarker Market

Figure 3 Segmentation Market Dynamics for Global Cancer Biomarker Market

Figure 4 Global Cancer Biomarker market Share, by Type 2016

Figure 5 Global Cancer Biomarker market Share, by Application 2016

Figure 6 Global Cancer Biomarker Market Share, by End Users, 2016

Figure 7 Global Cancer Biomarker Market Share, by Region, 2016

Figure 8 North America Cancer Biomarker Market Share, by Country, 2016

Figure 9 Europe Cancer Biomarker Market Share, by Country, 2016